Tuesday, April 20, 2021

Mankind Pharma eyes 50% revenue from chronic therapy drugs in 3 years

With the launch, the company has become the first Indian and second global firm to develop the drug, which is a generic version of Abbott's Duphaston

from Today's Paper https://ift.tt/3uYyPZa
via

No comments:

Post a Comment

If you have any doubts please let me know!

India's low score on GVC a starting point for recovery from pandemic: AIIB

India rated 7.4 percentage points below the average global value chain participation rate for emerging economies from Today's Paper ht...